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Abstract
Background: S-nitrosoglutathione (GSNO) and S-nitroso-N-acetlypenicillamine (SNAP) are two
of the most common sources of nitric oxide (NO) in the biomedical field. Vitamin C has been
known to accelerate the decomposition of GSNO and SNAP increasing the release and availability
of NO which is cytotoxic at non-physiological concentrations. The study investigates any potential
detrimental effect of vitamin C and GSNO, vitamin C and SNAP on glucose metabolism in
normotensive and normoglycemic dogs.
Results: The results showed that administration of vitamin C (50 mg/kg) and GSNO (35 mg/kg &
50 mg/kg), or vitamin C (50 mg/kg) and SNAP (10 mg/kg) to overnight fasted dogs resulted in
significant elevation of the blood glucose levels, attaining maximum level at the 2.0 or 2.5 h time
point postprandially. The elevated blood glucose levels were due to significant reduction in plasma
insulin levels in the dogs treated with vitamin C and GSNO, or vitamin C and SNAP (P < 0.05). The
decreased insulin response was associated with significant elevation of nitric oxide produced from
GSNO and SNAP co-administered with vitamin C, as assessed by plasma nitrate/nitrite levels.
Conclusions: The results indicate that enhanced NO release by vitamin C affects postprandial
blood glucose and plasma insulin levels and the reduced glucose tolerance is mainly due to impaired
insulin release. The clinical relevance of the findings of this study suggest that hypertensive diabetic
patients treated with GSNO or SNAP, who are on vitamin C supplements may be more
predisposed to further decrease in their glycemic control.
Background
Vitamin C (ascorbic acid) is a naturally occurring antioxi-
dant in human plasma and is capable of scavenging super
oxide anion [1]. Vitamin C levels in plasma and tissues
have been reported to be significantly lower than normal
in diabetic animals and humans, and might contribute to
the complications found at the late stages of diabetes [2].
Chronic vitamin C administration has beneficial effects
upon glucose and lipid metabolism in aged non-insulin
dependent (type 2) diabetic patients [3], and high-dose
supplementation may have beneficial effect in type 1 dia-
betes [4]. However, research carried out by investigators
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examining the adverse effects of vitamin C, discovered
that elevated plasma ascorbic acid delays insulin response
to a glucose challenge in normoglycemic adults, thereby
prolonging the postprandial hyperglycemia [5]. On the
other hand, other researchers have found that large doses
of vitamin C administered intravenously did not alter glu-
cose tolerance and fasting glucose levels, nor fasting se-
rum levels in normal or in obese subjects [6].
Nitric oxide-donor drugs decompose in the body, by a va-
riety of mechanisms, to generate NO. Initial clinical stud-
ies of s-nitrosothiols such as S-nitrosoglutathione
(GSNO) and S-nitroso-N-acetlypenicillamine (SNAP)
suggest that they may be of benefit in a variety of cardio-
vascular disorders [7]. In animals and human beings,
GSNO has significant antiplatelet action at doses that
cause little or no cardiovascular effect [8]. It is used thera-
peutically as an arterio-selective vasodilator [9] and a
platelet-selective anti-thrombotic agent [10]. Reducing
agents such as glutathione and vitamin C can stimulate
decomposition of GSNO and SNAP by chemical reduc-
tion of transition metal ions such as Cu2+[11]. Enhanced
release of NO from GSNO has been shown to augment
the hypotensive response to this agent [12]. The effects of
vitamin C on the NO-like bioactivity of exogenous GSNO
and SNAP as it relates to carbohydrate metabolism is un-
clear and serves the purpose of this study.
Experimental evidence from animals studies suggest that
GSNO and SNAP had a beneficial effect of reducing blood
pressure, however this was associated with decreased glu-
cose tolerance [13,14]. Therefore, we sought to test the hy-
pothesis that co-administration of vitamin C and GSNO,
or vitamin C and SNAP in an animal model may possibly
result in a potential detrimental effect that could include
further deterioration of glycemic control.
Results
Effects of vitamin C and NO donors (GSNO & SNAP) on 
blood glucose levels
The glucose tolerance curve of dogs treated with 35 mg/kg
of GSNO and 50 mg/kg of vitamin C was elevated above
that of dogs treated with only 35 mg/kg of GSNO at the
2.0-h and 2.5-h time points (Figure 1). Statistical signifi-
cant differences in mean postprandial blood glucose con-
centrations between the two groups were observed at the
2.0-h and 2.5-h time points with values of 9.16  0.49
mmol/L and 9.33  0.32 mmol/L in vitamin C and
GSNO-treated dogs. These values were compared with
7.11  0.40 mmol/L and 7.38  0.33 mmol/L respectively
in GSNO-treated dogs (P < 0.05). There were significant
differences between the integrated area under the blood
glucose concentration-time curve of dogs treated with vi-
tamin C and GSNO, 1562.10  101.40 mmol/L  150 min
compared with 1398.00  69.00 mmol/L  150 min in
GSNO-treated dogs (P < 0.05). Further statistical analysis
showed that areas under the blood glucose concentration-
time curve differ significantly between vitamin C and
GSNO-treated dogs, those treated with 20 mg/kg of capto-
pril (1136.70  69.00 mmol/L  150 min; P < 0.05), and
controls administered with water (1159.50  72.00
mmol/L  150 min; P < 0.05).
The elevated mean blood glucose concentrations of dogs
treated with 50 mg/kg of GSNO and 50 mg/kg of vitamin
C, and those treated with 50 mg/kg of GSNO were compa-
rable from 0.5-h to 1.0-h postprandial time points (Figure
2). However, after the 1.0-h time point, the glucose toler-
ance curve for vitamin C and GSNO-treated dogs shifted
upward. There were significant differences at the 1.5-h
and 2.0-h time points with values of 10.22  0.49 mmol/
L and 10.23  0.37 mmol/L respectively in the GSNO and
Figure 1
Line graphs showing the effect of 20 mg/kg captopril (Ќ), 35
mg/kg of S-nitrosoglutathione (), 50 mg/kg of vitamin C and
35 mg/kg of S-nitrosoglutathione () on blood glucose levels.
Water is used as the control solvent (▲ ). Statistical signifi-
cant difference between GSNO-treated dogs and those
treated with vitamin C and GSNO at different time points
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vitamin C-treated dogs, compared with 8.82  0.58
mmol/L and 8.44  0.37 mmol/L respectively in the
GSNO-treated dog (P < 0.05). There were significant dif-
ferences between the integrated area under the blood glu-
cose concentration-time curve of dogs treated with
vitamin C and GSNO, 1722.60  75.30 mmol/L  150
min compared with 1591.50  70.50 mmol/L  150 min
in GSNO-treated dogs (P < 0.05). Further statistical anal-
ysis showed that areas under the blood glucose concentra-
tion-time curve differ significantly between vitamin C and
GSNO-treated dogs and those treated with 20 mg/kg of
captopril (P < 0.05), and controls administered with water
(P < 0.05).
The elevated mean plasma glucose concentrations in dogs
treated with 10 mg/kg of SNAP and 50 mg/kg of vitamin
C, and those treated with 10 mg/kg of SNAP were compa-
rable from 0 to 1.5-h time points (Figure 3). However, at
this point the glucose tolerance curve for vitamin C and
SNAP-treated dogs shifted upward and there was signifi-
cant difference at the 2.5-h time point with value of 9.49
 0.10 mmol/L in the SNAP and vitamin C-treated dogs.
This was compared with 7.37  0.57 mmol/L in the SNAP-
treated dogs (P < 0.05). The integrated areas under the glu-
cose concentration-time curve differ significantly between
vitamin C and SNAP-treated dogs (1614.76  71.40
mmol/L   150 min) and those treated with SNAP
(1511.70  131.60 mmol/L  150 min; P < 0.05), 20 mg/
kg of captopril (P < 0.05), and controls administered with
water (P < 0.05).
Effects of vitamin C and NO donors (GSNO & SNAP) on 
plasma insulin levels
In response to a glucose load, the mean plasma insulin
concentration in dogs treated with GSNO increased to
maximum of 15.60  0.91 IU/ml after 1.0-h postprandi-
al and decreased steadily to 8.20  0.91 IU/ml after 2.5-
Figure 2
Line graphs showing the effect of 20 mg/kg captopril (Ќ), 50
mg/kg of S-nitrosoglutathione (), 50 mg/kg of vitamin C and
50 mg/kg of S-nitrosoglutathione () on blood glucose levels.
Water is used as the control solvent (▲ ). Statistical signifi-
cant difference between GSNO-treated dogs and those
treated with vitamin C and GSNO at different time points
















































Line graphs showing the effect of 20 mg/kg captopril (Ќ), 10
mg/kg of S-nitroso-N-acetylpenicillamine (), 50 mg/kg of
vitamin C and 10 mg/kg of S-nitroso-N-acetylpenicillamine
() on blood glucose levels. Water is used as the control
solvent (▲ ). Statistical significant difference between SNAP-
treated dogs and those treated with vitamin C and SNAP at
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h postprandial (Figure 4). The mean plasma insulin con-
centration in dogs treated with 50 mg/kg of GSNO and vi-
tamin C (50 mg/kg) increased gradually to 9.50  0.70
IU/ml at the 1.0 h time point, and then decreased to 7.20
 0.70 IU/ml at the 2.0-h postprandial time point. Statis-
tically significant differences between the mean plasma
insulin levels of dogs treated with 50 mg/kg of GSNO, and
those treated with 50 mg/kg GSNO and vitamin C (50
mg/kg) were observed at the 1.0-h and 1.5-h time points
(P < 0.05). The mean plasma insulin concentrations in the
dogs treated with 50 mg/kg of vitamin C and 50 mg/kg of
GSNO, or 50 mg/kg of GSNO was significantly altered
compared to those of controls or captopril-treated dogs (P
< 0.05). There were significant differences between the in-
tegrated area under the plasma insulin concentration-time
curve of dogs treated with vitamin C and GSNO, 1314.10
 125.80 mmol/L  150 min. This is compared with
2001.00  164.70 mmol/L  150 min for GSNO-treated
dogs (P < 0.05), 3959.40  367.2 mmol/L  150 min in
captopril-treated dogs (P < 0.05), and 4448.10  302.10
mmol/L  150 min for controls administered with water
(P < 0.05).
The decreased insulin response to the oral glucose chal-
lenge was depicted by mean plasma insulin concentration
of 28.00  1.50 IU/ml at the 1.0-h postprandial time
point in dogs treated with 50 mg/kg of vitamin C and 10
mg/kg of SNAP compared with 35.50  0.50 IU/ml in
dogs treated with 10 mg/kg of SNAP (P < 0.05; Figure 5).
Areas under the plasma insulin concentration-time curve
did differ significantly between vitamin C and SNAP-treat-
ed dog (4814.7  493.5 mmol/L  150 min) compared
with 6561.00  500.40 mmol/L  150 min for SNAP-treat-
ed dogs (P < 0.05). Further statistical analysis showed that
areas under the plasma insulin concentration-time curve
differ significantly between vitamin C and SNAP-treated
dogs, those treated with 20 mg/kg of captopril (P < 0.05),
and controls administered with water (P < 0.05).
Figure 4
Line graphs showing the effect of 20 mg/kg captopril (Ќ), 50
mg/kg of S-nitrosoglutathione (), 50 mg/kg of vitamin C and
50 mg/kg of S-nitrosoglutathione () on plasma insulin levels.
Water is used as the control solvent (▲ ). Statistical signifi-
cant difference between GSNO-treated dogs and those
treated with vitamin C and GSNO at different time points





















































Line graphs showing the effect of 20 mg/kg captopril (Ќ), 10
mg/kg of S-nitroso-N-acetylpenicillamine (), 50 mg/kg of
vitamin C and 10 mg/kg of S-nitroso-N-acetylpenicillamine
() on plasma insulin levels. Water is used as the control sol-
vent (▲ ). Statistical significant difference between SNAP-
treated dogs and those treated with vitamin C and SNAP at
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Determination of plasma nitrate/nitrite and vitamin C lev-
els
The plasma nitrate/nitrite concentration increased two-
fold over the basal value after 0.5 h, in dogs treated with
of 50 mg/kg of GSNO (Figure 6). The plasma nitrate/ni-
trite concentration increased from 12.67  0.47 M to
24.53  0.48 M after 0.5 h, and then a steadily increased
to a peak value of 27.13  1.86 M after 2.0 h. There was
a slight decrease to 24.07  0.23 M after 3.0 h. On ad-
ministration of 50 mg/kg of GSNO and 50 mg/kg of vita-
min C, the plasma nitrate/nitrite concentration increased
from 14.70  0.47 M to 40.00  3.85 M after 1.5 h, and
then gradually decreased to 37.35  1.10 M after 2.5 h.
The plasma nitrate/nitrite levels differ significantly be-
tween these two groups at all the time point (P < 0.05)
throughout the experiment after drug administration, and
also between vitamin C and GSNO-treated dogs, and cap-
topril treated-treated dogs (P < 0.05). Plasma nitrate/ni-
trite concentration also differ significantly between
vitamin C and GSNO-treated dogs, and controls adminis-
tered with water (P < 0.05).
The plasma nitrate/nitrite concentration of dogs treated
with 10 mg/kg of SNAP increased by 8  0.5 % after 0.5 h,
from 12.04  0.30 M to 13.00  0.23 M (Figure 7). This
marginal rise in the plasma nitrate/nitrite concentration
was followed by gradual increases over the 3.0 h period,
with a maximum level of 19.12  0.5 M after 2.5 h. The
plasma nitrate/nitrite concentration increased by 32  2 %
over the basal value after 0.5 h, in dogs treated with of 10
mg/kg of SNAP and 50 mg/kg of Vitamin C. The plasma
nitrate/nitrite concentration increased from 12.15  0.30
M to 15.01  0.48 M after 0.5 h, and then a steadily in-
creased to a peak value of 28.35  1.50 M after 3.0 h. Sta-
tistically significant differences between the plasma
nitrate/nitrite concentration of SNAP (10 mg/kg) and vi-
tamin C-treated dogs, and those treated with SNAP (10
mg/kg) were observed at 1.5-h to 3.0-h time points (P <
0.05). The mean plasma nitrate/nitrite concentration re-
mained elevated in SNAP (10 mg/kg) and vitamin C-treat-
ed dogs, compared with those of controls administered
with or captopril-treated dogs in which no increase in this
parameter was observed (P < 0.05). Mean fasting plasma
ascorbic concentration was in the normal range of 0.7 –
1.2 mg/100 ml. The increase in mean vitamin C concen-
tration in plasma after administration of 50 mg/kg of vita-
min C ranged from 1.03  0.05 mg/100 ml – 2.79  0.30
mg/100 ml that is comparable with literature values at
similar vitamin C intake [15].
Discussion
We have showed previously that GSNO and SNAP had
beneficial effects based on their reduction of blood pres-
sure in normotensive dogs [13,14]. This was related to en-
hanced generation and release of NO. In addition,
findings from the same study showed that the decreased
glucose tolerance observed was associated with decreased
insulin release [13,14]. In the present investigation, we
tested the hypothesis that co-administration of vitamin C
and GSNO, or vitamin C and SNAP in an animal model
may possibly result in a potential detrimental effect that
could include further deterioration of glycemic control.
The salient finding of this study is that enhanced NO re-
lease from GSNO and SNAP by vitamin C, affects post-
prandial blood glucose and plasma insulin levels, and
reduced glucose tolerance is mainly due to impaired insu-
lin release. Therefore vitamin C deteriorates the decreased
glucose tolerance by the NO donors. This observation
strongly support the fact that elevated plasma ascorbic
acid may delay or decrease insulin response to a glucose
challenge in an animal model, thereby prolonging the
postprandial hyperglycemia. The results from this study
are in agreement with previous observations that indicat-
ed that elevated plasma vitamin C delays the insulin re-
Figure 6
Line graphs showing the effect of 20 mg/kg captopril (Ќ), 50
mg/kg of S-nitrosoglutathione and 50 mg/kg of Vitamin C (),
50 mg/kg of S-nitrosoglutathione () on plasma nitrate/
nitrite concentrations. Water is used as the control solvent
(▲ ). Statistical significant difference between GSNO-treated
dogs and those treated with vitamin C and GSNO at differ-
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sponse to a glucose challenge in normoglycemic adults,
perhaps by competitively inhibiting glucose uptake by
pancreatic beta-cells [5].
In the present study the insulin response to a glucose chal-
lenge in the dogs treated with vitamin C and SNAP or vi-
tamin C and GSNO was notably delayed and significantly
decreased compared with values in dogs treated with only
SNAP or GSNO, captopril or controls administered with
water. A likely explanation for the initial delayed in insu-
lin release could be that as the blood glucose began to rise
in the initial minutes after the glucose challenge, compe-
tition between glucose and vitamin C for transport into
the islet cells may have slowed glucose entry, thereby im-
pairing the glucose-sensing apparatus of the islet cells.
Hence, less insulin was secreted 0.5-h postprandial in the
vitamin C and GSNO or vitamin C and SNAP-treated
dogs, than in dogs treated with GSNO, SNAP, captopril or
controls administered with water. Decreased insulin se-
cretion would also explain why mean blood glucose was
significantly elevated in the vitamin C and GSNO, or vita-
min C and SNAP-treated dogs at the 2.0 and 2.5-h time
points compared with dogs treated with GSNO or SNAP,
captopril or control administered with water thereby pro-
longing postprandial hyperglycemia. As evident by com-
parisons of the area circumscribed by the plasma insulin
response curve, the quantity of insulin released by the
pancreas was significantly affected by the co-administra-
tion of vitamin C with the NO-donors, suggesting that in-
adequate insulin was secreted to dispose of the glucose
load in the vitamin C and GSNO, or vitamin C and SNAP-
treated dogs. The blood glucose values for the vitamin C
and GSNO or vitamin C and SNAP-treated dogs were well
outside of the normal limits at the 2.0-h and 2.5-h time
points, and significantly elevated above their counterparts
treated with only GSNO or SNAP (P < 0.05) whose values
were also outside the normal range, suggesting further de-
terioration of glucose tolerance.
Nitric oxide is toxic at high physiological concentration
where it appears to function as a cellular effector molecule
that mediates both cytostatic and cytotoxic effect [16].
Previous evidence have indicated that pancreatic islet cells
exposed to the NO-donor streptozotocin caused lasting,
damage to the beta-cells, characterized by a persistent im-
pairment in glucose metabolism and a defective insulin
response [17], and that the NO-donor sodium nitroprus-
side caused lysis of islet cells in a concentration- and time-
dependent manner. The mechanism by which these drugs
affect the pancreas could account for the hyperglycemic
effect observed in the dogs treated with GSNO and SNAP.
Vitamin C, an important determinant of the intracellular
redox state, has been known to accelerate the decomposi-
tion of GSNO and SNAP increasing the release and avail-
ability of NO. The modulation of the bioactivity of GSNO
by ascorbic acid is dependent on the presence of transition
metal ions [18]. Reduced transition metal ions such as
Cu+ catalyze the decomposition of GSNO and SNAP than
do their oxidized forms eg, Cu2+[18]. Elevated levels of
plasma nitrate/nitrite levels, assessed as NO production,
was observed in vitamin C and GSNO or vitamin C and
SNAP-treated dogs indicating enhanced NO release. The
prolonged and exacerbated hyperglycemic effect could be
explained in terms of the fact that exposure of the beta-
cells to increased NO levels resulting in further deteriora-
tion in beta-cell function characterized by impairment in
glucose metabolism and defective insulin response [17].
The enhanced NO released caused marked reduction in
the plasma insulin levels which are in agreement with pre-
vious observations which suggest that NO acts as a nega-
tive modulator of glucose stimulated insulin secretion,
thus accounting for the pronounced hyperglycemic effect
[19].
The solvent water was administered to the control dogs.
Water was used because it can be considered as an "inac-
tive treatment" with no capacity to enhance the genera-
tion of NO from its donors or possessing any antioxidant
Figure 7
Line graphs showing the effect of 20 mg/kg captopril (Ќ), 10
mg/kg of S-nitroso-N-acetylpenicillamine (), 10 mg/kg of S-
nitroso-N-acetylpenicillamine and 50 mg/kg of vitamin C ()
on plasma nitrate/nitrite concentration. Water is used as the
control solvent (▲ ). Statistical significant difference between
SNAP-treated dogs and those treated with vitamin C and
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properties. Captopril an angiotensin converting enzyme
inhibitor was also used in the study. Reports on the meta-
bolic effects of captopril on oral glucose tolerance and in-
sulin action in the literature are conflicting. Studies have
shown that captopril enhanced the effects of bradykinin,
which via a stimulation of B2 receptors caused the release
of NO and of prostanoids, which resulted in increased
blood glucose levels and reduced plasma insulin levels
[20]. However the results from this study showed that cap-
topril had no effect on oral glucose tolerance and insulin
levels, and plasma nitrate/nitrite levels in captopril-treat-
ed dogs was comparable with age-matched controls ad-
ministered with water. The results from our study is
supported by similar findings by other investigators,
where experiments carried out on spontaneously hyper-
tensive rats showed that captopril reduced blood pressure
and cardiac mass, but had no significant effect on oral glu-
cose tolerance and insulin action [21]. In addition, analy-
sis of results from the treatment of hypertensive patients
with captopril showed that it had no effect on carbohy-
drate metabolism, which is advantageous for the treat-
ment of hypertensive patients [22].
It is suggested that the lack of effect of captopril on glucose
tolerance might be due to different tissue metabolisation
and/or penetration of captopril, which could arise from
(1) the redox status of the tissue, which limit captopril bi-
oavailability by favouring the formation of disulfurs
through captopril dimerzation or reaction with a different
thiol compound; and (2) the existence of organ rennin-
angiotensin systems with different levels of expressions
and/or activity of angiotensin converting enzymes [23].
Captopril has been reported to possess hydroxyl and hy-
pochlorous acid scavenging effects, which could contrib-
ute to its therapeutic activity in the clinical settings [24].
The sulfhydryl moiety (-SH) of captopril is responsible for
its antioxidant properties [25] and it is suggested that cap-
topril may protect tissues from oxidative damage by in-
creasing enzymatic and non-enzymatic antioxidant
deference [23] and inhibit microsomal lipid peroxidation
[26].
Assessment of the clinical relevance of the present results
should take into account the fact that ascorbic acid influ-
ences the decomposition of SNAP in rat striatal slices [27].
Islet cells were found to be very susceptible to the cytotox-
ic action of NO while hepatocytes and endothelial cells
were relatively resistant [28]. Epidemiological studies
have indicated that an association between increased in-
take of vitamin C and reduced risk of coronary disease
[29]. This is the first documentation of the potential det-
rimental effect of vitamin C and NO donors on glucose
tolerance in an animal model. The clinical relevance of the
findings of this study allows us to suggest that hyperten-
sive patients treated with GSNO or SNAP, who are on vi-
tamin C supplements may be more predisposed to further
decrease in their glycemic control. These findings should
encourage further research on the effect of vitamin C sup-
plementation on glucose homeostasis and insulin release
in clinical settings involving hypertensive and diabetic pa-
tients is warranted. The elucidation of the underlying
mechanism might help us to understand the reaction of
antioxidants with NO donors and it is therefore suggested
that vitamin C supplementation should be limited in pa-
tients treated with these drugs.
Conclusion
The findings of this study indicates that enhanced NO re-
lease affects postprandial blood glucose and plasma insu-
lin levels and reduced glucose tolerance is mainly due to
impaired insulin release. Vitamin C deteriorates the de-
creased glucose tolerance by the NO donors. This the first
report of the detrimental effect of vitamin C on glucose
metabolism in normoglycaemic dogs, treated with NO
donors, and furthers current knowledge on the associa-
tion of NO donors and antioxidants. An examination of
the possible effect of vitamin C supplementation on glu-
cose homeostasis and insulin release in clinical settings
involving hypertensive and diabetic patients is warranted.
Methods
Animal care – experimental design
The protocol was conducted in accordance with the guide-
lines of the University of the West Indies Animal Commit-
tee. Mongrel dogs (15 males and 15 females) of 2–3 years,
with average weight of 12.4  0.4 kg were obtained from
the Pre-Clinical Animal House of the Department of Basic
Medical Sciences, University of the West Indies. The ani-
mals were maintained in the animal house under the su-
pervision of attendants and a veterinary consultant. Dogs
were fed on a diet of Purina Laboratory Chow (Purina, St.
Louis MO. USA) and water administered ad libitum. The
dogs were divided into five groups of six and each had
normal glucose tolerance as indicated by an oral-glucose
tolerance test (OGTT) performed at the beginning of the
study. The first group of dogs was administered with water
(controls), the second group was treated with 20 mg/kg of
captopril, and the third group with 35 mg/kg of GSNO,
then GSNO (35 mg/kg) and 50 mg/kg of vitamin C. The
fourth group was treated with 50 mg/kg of GSNO, then
GSNO (50 mg/kg) and 50 mg/kg of vitamin C and the
fifth group was treated with 10 mg/kg of SNAP, then
SNAP (10 mg/kg) and 50 mg/kg of vitamin C.
Oral glucose tolerance test
An oral glucose tolerance test was performed on each dog.
Briefly, after an 18-h fast, dogs were anesthetized with so-
dium pentabarbital (30 mg/kg i.v.). Subsequently, the
fasting blood sample [0'] was taken and in control exper-
iments 20 mg/kg body weight of captopril (Sigma Chem-BMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/18
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icals Co. Ltd, St. Louis MO. U.S.A.) dissolved in water was
administered intravenously. In test experiments, S-ni-
troso-N-acetylpenicillamine dissolved in dimethylsul-
phoxide (DMSO) was administered at a dose of 10 mg/kg
body weight to the dogs at the 0' time point after a fasting
blood sample was taken. S-nitrosoglutathione, dissolved
in water (2 ml) was administered at doses of 35 or 50 mg/
kg body weight to the dogs also at the 0' time point. Addi-
tional blood samples were collected 0.5, 1.0 1.5, 2.0, and
2.5-h time points after administration of a glucose load of
1.75 g/kg body weight. Each sample was collected in an
EDTA tube and immediately placed on ice for subsequent
biochemical analysis.
The plasma glucose levels were determined by the glucose
oxidase method [30] and the absorbance measured at 420
nm using a Spectrophotometer (Spectronic Genesys). The
plasma insulin concentrations were measured by radioim-
munoassay with a commercial kit (Diagnostic Products
Corporation, Los Angeles, California, USA), and radioac-
tivity was determined using a gamma counter (Abbott
Auto Logic Gamma Counter). The plasma ascorbic acid
concentration was determined using the 2,4-nitrophenyl-
hydrazine method of Omaye et al [31].
Nitric oxide formation was measured as plasma nitrate/ni-
trite concentration, using the Griess reaction [32]. Briefly,
50 l of plasma was deproteinized by the addition of 100
l of 35% sulfosalicylic acid. Treated samples were mixed
by vortexing every 5 minutes and allowed to react for 30
minutes at room temperature. These were centrifuged at
10,000 g for 15 minutes. Two hundred microlitres (200
l) of the supernatant was added to 4 ml of de-ionized wa-
ter in a 1:20 dilution for analysis. The sample was passed
through a copper-cadmium column of an autoanalyser
(Autoanalyser, Technicon Instruments Corporation, Tar-
rytown, N.Y. U.S.A.), to reduce nitrate to nitrite. The re-
sulting nitrite concentration was determined by the
addition of Griess reagent [0.1% sulfanilamide in 5% con-
centrated phosphoric acid and 0.1% N-(1-naphthyl)-eth-
ylenediamine dihydrochloride] to form a purple azo dye
and the nitrite was quantified using NaNO2. The data is
presented as plasma nitrate/nitrite concentration.
Calculations and statistics
Results are reported as the mean  S.E.M. Integrated area
under the curve (iUAC) was calculated by subtracting the
rectangle corresponding to the basal value from the total
area under the curve [33]. Mean curved areas were com-
pared by using the paired Student's t test for controls and
all the groups in the test experiments. Analysis of variance
(ANOVA) followed by the Bonferroni multiple compari-
son test [34] was used to examine differences in blood glu-
cose, plasma insulin and plasma nitrate/nitrite
concentrations at each time interval during the OGTT.
Analysis of the data was done using the Sigma Plot and
Sigma Statistics software packages (Jandel Scientific). A
probability value of less than 0.05 was considered to indi-
cate significance in all cases.
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